Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6% - Should You Sell?

Key Points

• Kailera Therapeutics shares fell 8.6% to about $16.93, with trading volume roughly 58% below the average session volume.
• Analyst views are mixed: the stock has a “Moderate Buy” consensus and a $42.75 average target price, but recent coverage included “Sell” ratings alongside “Buy” and “Outperform” recommendations.
• The company reported a quarterly loss of $1.09 per share, missing expectations by $0.35; meanwhile, several institutional investors established new positions worth more than $200 million combined.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) were down 8.6% on Friday . The stock traded as low as $16.81 and last traded at $16.93. Approximately 300,058 shares were traded during mid-day trading, a decline of 58% from the average session volume of 718,964 shares. The stock had previously closed at $18.53.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on KLRA shares. Wall Street Zen cut Kailera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 30th. Weiss Ratings started coverage on Kailera Therapeutics in a research report on Friday, August 14th. They issued a "sell (d)" rating for the company. Zacks Research upgraded shares of Kailera Therapeutics to a "hold" rating in a research note on Wednesday, May 13th. William Blair began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $48.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kailera Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 8.6%

The company has a market cap of $2.19 billion and a price-to-earnings ratio of -0.00. The business's 50 day simple moving average is $19.16.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities research analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at about $309,000. Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new position in shares of Kailera Therapeutics in the second quarter worth approximately $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source